DISEASE SCANNER
Global Incurable Diseases Tracker
Acute Lymphoblastic Leukemia (ALL)
The most common childhood cancer, characterized by uncontrolled proliferation of immature lymphoid cells (lymphoblasts) in bone marrow and blood. Peak incidence at 2-5 years. Multiple subtypes with varying prognosis.
80.0K
17
Symptoms
Treatment Options
Risk Factors
Diagnostic Methods
- 1Biopsy
- 2Imaging (CT, MRI, PET)
- 3Tumor markers
- 4Genetic testing
- 5Endoscopy
- 6Blood tests
- 7Screening programs
Prognosis
Childhood ALL has 85-90% long-term survival with modern intensive chemotherapy protocols. Adult ALL survival is 40-50%, improving with pediatric-inspired regimens and targeted therapies. High-risk genetic features (Philadelphia chromosome, MLL rearrangements) reduce survival to 30-40% without stem cell transplant. Relapsed disease has 30-50% salvage rate with CAR-T cell therapy or transplant. Treatment duration is 2-3 years for standard-risk patients.
Prevention
- Smoking cessation
- Sun protection
- Healthy diet
- Regular exercise
- Vaccination (HPV, HBV)
- Screening programs
- Limit alcohol
- Maintain healthy weight
Research Status
Multi-agent chemotherapy with risk stratification. Survival >90% for standard-risk ALL. CAR-T cell therapy (tisagenlecleucel) for B-ALL. Blinatumomab for MRD-positive. Tyrosine kinase inhibitors for Ph+ ALL. Cranial radiation rarely used.
Affected Countries
Sources
- https://www.cancer.gov
- https://www.who.int/cancer
- https://www.cancer.org
Medical Disclaimer
This information is for educational purposes only. Always consult healthcare professionals for medical advice, diagnosis, and treatment.